E!2238 SCAND
| Reference number | |
| Coordinator | Iscaff Pharma AB |
| Funding from Vinnova | SEK 4 786 425 |
| Project duration | February 2023 - July 2025 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
A synthetic, 3D scaffold has been developed and tested with cancer cells and CAR-T cells. The project has established methods to measure treatment effects through viability assessments, RNA and gene expression analyses for selected cancers, and immune system and cell regulation. The methods have been refined to validate the effectiveness of new CAR-T treatments. Additionally, a platform has been created to study combination therapies, such as chemotherapy combined with kinase inhibitors.
Expected long term effects
The project is expected to contribute in the long term to developing more relevant and reproducible preclinical models for the evaluation of cancer immunotherapies. Synthetic scaffolds can reduce the need for animal testing and improve the prediction of treatment effects. The methodology also enables studies of combination treatments and resistance mechanisms, which can support the future development of more accurate and personalised therapies.
Approach and implementation
The project was carried out as planned, with some extension due to a reorganisation following the sudden death of the CEO of Iscaff Pharma in March 2024, as well as technical difficulties in producing the synthetic scaffolds. These issues were addressed through method adjustments and increased collaboration between the parties. Regular digital meetings took place, and all key project objectives were achieved.